Journal of Pharmacology and Experimental Therapeutics 2005-06-01

Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.

Eugene T Grygielko, William M Martin, Christopher Tweed, Peter Thornton, John Harling, David P Brooks, Nicholas J Laping

Index: J. Pharmacol. Exp. Ther. 313 , 943-951, (2005)

Full Text: HTML

Abstract

SB-525334 (6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline) has been characterized as a potent and selective inhibitor of the transforming growth factor-beta1 (TGF-beta1) receptor, activin receptor-like kinase (ALK5). The compound inhibited ALK5 kinase activity with an IC(50) of 14.3 nM and was approximately 4-fold less potent as an inhibitor of ALK4 (IC(50) = 58.5 nM). SB-525334 was inactive as an inhibitor of ALK2, ALK3, and ALK6 (IC(50) > 10,000 nM). In cell-based assays, SB-525334 (1 microM) blocked TGF-beta1-induced phosphorylation and nuclear translocation of Smad2/3 in renal proximal tubule cells and inhibited TGF-beta1-induced increases in plasminogen activator inhibitor-1 (PAI-1) and procollagen alpha1(I) mRNA expression in A498 renal epithelial carcinoma cells. In view of this profile, SB-525334 was used to investigate the role of TGF-beta1 in the acute puromycin aminonucleoside (PAN) rat model of renal disease, a model of nephritis-induced renal fibrosis. Orally administered doses of 1, 3, or 10 mg/kg/day SB-525334 for 11 days produced statistically significant reductions in renal PAI-1 mRNA. Also, the compound produced dose-dependent decreases in renal procollagen alpha1(I) and procollagen alpha1(III) mRNA, which reached statistical significance at the 10-mg/kg/day dose when compared with vehicle-treated PAN controls. Furthermore, PAN-induced proteinuria was significantly inhibited at the 10-mg/kg/day dose level. These results provide further evidence for the involvement of TGF-beta1 in the profibrotic changes that occur in the PAN model and for the first time, demonstrate the ability of a small molecule inhibitor of ALK5 to block several of the markers that are predictive of fibrosis and renal injury in this model.


Related Compounds

Related Articles:

Mesenchymal activin-A overcomes defective human trisomy 21 trophoblast fusion.

2011-12-01

[Endocrinology 152 , 5017-28, (2011)]

Activin-Like Kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline

2009-01-01

[Am. J. Pathol. 174(2) , 380-9, (2009)]

Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.

2007-05-15

[Clin. Cancer Res. 13 , 3087-3099, (2007)]

Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.

2007-08-01

[Exp. Mol. Pathol. 83 , 39-46, (2007)]

More Articles...